## Distinguishing MEN 1 from MEN 2A ### Key Differences **Key Point:** MEN 1 and MEN 2A are genetically and clinically distinct syndromes with non-overlapping tumor spectra. The presence of cutaneous manifestations (lipomas, collagenomas, angiofibromas) is pathognomonic for MEN 1 and absent in MEN 2A. ### Comparative Table | Feature | MEN 1 | MEN 2A | |---------|-------|--------| | **Gene** | MENIN (Chr 11q13) | RET proto-oncogene (Chr 10q11) | | **Parathyroid involvement** | >90% (multiglandular hyperplasia) | 20–30% (mild hyperplasia) | | **Medullary thyroid cancer** | Absent | 100% (nearly universal) | | **Pheochromocytoma** | Absent | 50% | | **Cutaneous tumors** | Lipomas, collagenomas, angiofibromas | Absent | | **Pancreatic/GI NETs** | 60–70% (gastrinomas, insulinomas) | Absent | | **Mucosal neuromas** | Absent | Present (MEN 2B only) | **High-Yield:** Cutaneous lipomas and collagenomas are virtually diagnostic of MEN 1 and do NOT occur in MEN 2A, making this the single best discriminator. ### Clinical Pearl **Clinical Pearl:** MEN 1 is the "3 P's" syndrome: **P**ancreas (NETs), **P**arathyroid (hyperparathyroidism), **P**ituitary (prolactinoma). MEN 2A is "C-M-P": **C**alcitonin-secreting medullary thyroid cancer, **M**edullary thyroid cancer (100%), **P**heochromocytoma (50%). ### Why Cutaneous Features Distinguish MEN 1 Cutaneous manifestations (lipomas in 80%, collagenomas in 70%, angiofibromas in 85% of MEN 1 patients) are: - Visible and clinically apparent - Completely absent in MEN 2A - Not seen in sporadic hyperparathyroidism or other endocrine disorders - Often the earliest clinical clue to MEN 1 diagnosis [cite:Robbins 10e Ch 24] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.